Premium accounts now available! Sign up and create a premium account. Read more Close

Sign in

Sign in to personalize your content feed, follow keywords and sources you care about, bookmark content you like, and join the conversation by sharing your recommendations and comments.

Sign in with LinkedIn Sign in with Google

You can also sign in with your account. Don't have an account yet? Sign up

Your cookie settings

This site uses cookies. Some cookies are essential to make the site work and others help us to improve our services. Read more about cookies in our Privacy policy.

Choose your cookie preferences:

Advertisement

Image

[Articles] 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan

Journal content Created on 24 Oct 2026 The Lancet

Advertisement

Stats

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 82
  • Comments 0

Recommended by

  • No recommendations yet.

Do you recommend this? Please sign in. Yes No

Recommended

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement